Article info

other Versions

PDF

Extended report
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics

Authors

  1. Correspondence to Dr Thomas Frisell, Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm 17176, Sweden; thomas.frisell{at}ki.se
View Full Text

Citation

Frisell T, Baecklund E, Bengtsson K on behalf of the ARTIS Study group, et al
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics

Publication history

  • Received September 15, 2017
  • Revised November 23, 2017
  • Accepted November 27, 2017
  • First published December 13, 2017.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.